Yunkang Group Limited
HHKEX:23250.58
HKD
-0.01
(-2.54%)
ISIN
KYG9889T1067
CUSIP
G9889T106
Return %
Stock
S&P 500
1Y
-44.71
14.20
3Y
-95.17
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Yong Zhang
- Full Time Employees
- 1,064
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- No. 9 Yayingshi Road Guangzhou GD China
- IPO Date
- May 18, 2022
- Website
- yunkanghealth.com
- Similar Companies
- Business
- Yunkang Group Limited (2325.HK) is an investment holding company that operates as a medical operation service provider in the People's Republic of China, primarily engaged in diagnostic testing services through independent clinical laboratories and on-site diagnostic centers. The company offers three core business lines: diagnostic testing services for medical institution alliances, which assist hospitals in establishing or upgrading on-site diagnostic centers in areas such as infectious diseases, reproductive health, genetic diseases, and pathology, including testing technologies, professional technicians, standard operating procedures, diagnostic consultation, staff training, equipment procurement, smart IoT, and logistics assistance; diagnostic outsourcing services to hospitals, other medical institutions, and public health institutions, encompassing pathology tests, infectious disease diagnostic tests, and genetic reproduction and screening tests; and diagnostic testing services for non-medical institutions, such as personalized diagnostic testing, medical report consultation, and hospital referral services for financial institutions and insurance companies. Founded in 2008 and headquartered in Guangzhou, the company conducts operations across mainland China, with independent laboratories in key cities including Guangzhou, Chengdu, Shanghai, Hefei, Kunming, and Nanchang, offering approximately 3,800 testing items and processing over 10 million specimens annually as of December 31, 2024; it holds the largest number of ISO15189 and CAP dual-certified independent clinical labs in China and serves as the sole China branch of the Clinical and Laboratory Standards Institute (CLSI). Recent developments include strategic collaborations with the People's Government of Ouhai, Wenzhou City, and Wenzhou Medical University to build biomedical projects like joint innovation platforms, public service platforms, medical big data centers, regional diagnostic sharing centers, and talent training bases; partnerships with Zhangjiang Research Institute of Fudan University for a Collaborative Innovation and Transformation Center in medical diagnostics; and alliances with Central University of Finance and Economics' Greater Bay Area Research Institute for industry-education fusion and incubation platforms, alongside increased R&D investment to RMB53 million in 2024 (7.4% of revenue) focused on AI digitalization, product innovation, and clinical applications amid revenue optimization and asset impairment provisions.